SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-24-009339
Filing Date
2024-03-26
Accepted
2024-03-26 08:11:05
Documents
18
Period of Report
2024-05-09

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A sava20240104_def14a.htm   iXBRL DEF 14A 659413
6 graph01.jpg GRAPHIC 54097
7 p01.jpg GRAPHIC 113427
8 p02.jpg GRAPHIC 147320
9 smlogo.jpg GRAPHIC 13290
  Complete submission text file 0001437749-24-009339.txt   2186999

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sava-20231231.xsd EX-101.SCH 7489
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20231231_def.xml EX-101.DEF 9573
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20231231_lab.xml EX-101.LAB 19436
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20231231_pre.xml EX-101.PRE 9596
21 EXTRACTED XBRL INSTANCE DOCUMENT sava20240104_def14a_htm.xml XML 131044
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41905 | Film No.: 24780983
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)